Ontuxizumab clinical trials
Also written MORAb-004.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ontuxizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MORAb-004
- 4
Studies by the year they started
6 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses ontuxizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)TerminatedPhase 2MorphotekNCT01507545Written as MORAb-004How we know
- Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic MelanomaCompletedPhase 2Eisai Inc.NCT01335009Written as MORAb-004 (monoclonal antibody)How we know
- Sarcoma Study of MORAb-004 Utilization: Research and Clinical EvaluationCompletedPhase 2MorphotekNCT01574716Written as MORAb-004How we know
- A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)CompletedPhase 1Eisai Co., Ltd.NCT01773434Written as MORAb-004How we know
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedPhase 1MorphotekNCT01748721Written as anti-endosialin/TEM1 monoclonal antibody MORAb-004How we know
- A Study of of MORAb-004 in Subjects With Solid TumorsCompletedPhase 1MorphotekNCT00847054Written as MORAb-004 (monoclonal antibody to TEM1)How we know
Codes
What other systems call ontuxizumab · ClinicalTrials.gg INT000390
- MeSH (NLM) C000604563ontuxizumabOne source NLM
- UNII (FDA) 0M2XT000YCONTUXIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q15708295OntuxizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82406OntuxizumabOne source FDA
- DrugBank DB16270One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604563 | ontuxizumab | One source NLM |
| UNII (FDA) | 0M2XT000YC | ONTUXIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15708295 | Ontuxizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82406 | Ontuxizumab | One source FDA |
| DrugBank | DB16270 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.